Incyte presented 54‑week data for its oral JAK1 inhibitor povorcitinib at the 2026 American Academy of Dermatology (AAD) Annual Meeting, marking the first long‑term evidence of sustained efficacy for the drug in hidradenitis suppurativa (HS).
The data demonstrate durable symptom relief and disease control over a year‑long period, providing the first long‑term efficacy evidence for povorcitinib in this indication. The results support the company’s strategy to position the drug as the first oral option in a market that currently relies on injectable biologics such as adalimumab, secukinumab, and bimekizumab.
Prevalence estimates for HS in the United States range from 0.10% to 1.2% of the population, indicating a sizable patient pool of several hundred thousand to a few million individuals. Only a minority of these patients receive advanced systemic therapy, underscoring the unmet need that povorcitinib could address.
Incyte has submitted new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA) and marketing authorization applications (MAAs) to the European Medicines Agency (EMA) for povorcitinib in moderate to severe HS. The drug is also being investigated for other indications, including nonsegmental vitiligo and prurigo nodularis.
"The 54‑week results from the STOP‑HS program deliver compelling, long‑term evidence supporting the potential of povorcitinib for patients with moderate to severe HS. Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical benefit with a manageable safety profile, underscoring its promise to help transform the HS treatment landscape as the first oral option. We look forward to advancing our regulatory applications in the U.S. and Europe," said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.